Volume and Location Analysis of Intracerebral Hemorrhage for the Appropriate Use of Andexanet Alfa.

ABSTRACT: Andexanet alfa was approved as a reversal agent for Factor Xa inhibitors in patients with uncontrolled or life-threatening bleeding, such as intracerebral hemorrhage. However, its use in cases of small hemorrhages remains controversial. This study determined the appropriate use of andexanet alfa on the basis of hematoma volume and location analysis. The study included consecutive patients with intracerebral hemorrhage who took Factor Xa inhibitors between January 2020 and December 2024. Individuals receiving standard care (January 2020-June 2022) and those being administered andexanet alfa (July 2022-December 2024) were compared and classified by hematoma volume (<5 mL, 5-30 mL, and >30 mL). Sixty-one patients were enrolled, with 27 and 34 patients receiving standard care and andexanet alf

SUBMITTER: Umemura T 

PROVIDER: S-EPMC12799336 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature